N-乙基-N-(2-吡咯烷基甲基)乙胺 | 121053-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-乙基-N-(2-吡咯烷基甲基)乙胺
• 英文名称: N-ethyl-N-(pyrrolidin-2-ylmethyl)ethanamine
• CAS: 121053-95-0
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: SWMHMAUXZINLIQ-UHFFFAOYSA-N

物化性质

• 沸点：
  197.5±8.0 °C(Predicted)
• 密度：
  0.872±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5,11-二氢-11-氯乙酰基-6H-吡啶并[2.3-b][1,4]苯并二氮卓-6-酮 、 N-乙基-N-(2-吡咯烷基甲基)乙胺 在 sodium carbonate 作用下， 以 乙腈 为溶剂， 反应 5.0h， 以13%的产率得到11-[2-[2-(diethylaminomethyl)pyrrolidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
  参考文献：
  名称：

  Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics

  摘要：

  On the basis of the cardioselective muscarinic receptor antagonist AF-DX 116 (2), a series of 11-substituted pyridobenzodiazepinones (9-35) was prepared and screened for their binding affinity to muscarinic receptors located in cardiac (M2) and glandular (M3) tissue. The ratio of IC50 values of the test compounds in the two different tissues was taken as a measure of cardiac (M2) receptor selectivity. Qualitative structure-selectivity relationships point to the fact that it is the spatial orientation of the protonated side-chain nitrogen atom in relation to the tricycle that is the main determinant for receptor subtype recognition and hence is important for the achievement of cardiac (M2) selectivity.

  DOI：

  10.1021/jm00128a008

文献信息

• [EN] FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUMAGILLOL, ET PROCÉDÉS CORRESPONDANTS DE FABRICATION ET D'UTILISATION
  申请人：ZAFGEN INC

  公开号：WO2017027684A1

  公开（公告）日：2017-02-16

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文披露了富马吉醇化合物及其在治疗医学疾病（如肥胖症）中的用途方法。提供了富马吉醇化合物的药物组合物和制备方法。这些化合物被认为具有对蛋氨酸氨肽酶2的活性。
• Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
  申请人：——

  公开号：US20030195190A1

  公开（公告）日：2003-10-16

  Novel amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

  氨基烷基取代的氮杂环戊烷、吡咯烷、哌啶和环庚烷的新型酰胺，以这些化合物作为药物组合物的用途，包含这些化合物的药物组合物，以及使用这些化合物和组合物进行治疗的方法。这些化合物显示出高度和选择性地结合到组胺H3受体，表明具有组胺H3受体拮抗、逆拮抗或激动活性。因此，这些化合物可用于治疗与组胺H3受体相关的疾病和疾病。
• Fumagillol heterocyclic compounds and methods of making and using same
  申请人：Zafgen, Inc.

  公开号：US10023561B2

  公开（公告）日：2018-07-17

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文部分公开了烟曲霉素化合物和用于治疗肥胖等疾病的方法。提供了药物组合物和制造烟嘧酚化合物的方法。这些化合物对蛋氨酰氨基肽酶 2 具有活性。
• TAFUSA, FUDZIO;EHJ, KADZUESI;TSUTSUI, XIRONORI
  作者：TAFUSA, FUDZIO、EHJ, KADZUESI、TSUTSUI, XIRONORI

  DOI：——

  日期：——
• ENGEL, WOLFHARD W.;EBERLEIN, WOLFGANG G.;MIHM, GERHARD;HAMMER, RUDOLF;TRU+, J. MED. CHEM., 32,(1989) N, C. 1718-1724
  作者：ENGEL, WOLFHARD W.、EBERLEIN, WOLFGANG G.、MIHM, GERHARD、HAMMER, RUDOLF、TRU+

  DOI：——

  日期：——